Biotech company Owkin announced that its rapid AI diagnostic solutions (RlapsRisk BC and MSIntuit CRC) for breast cancer and colorectal cancer have been approved for use in Europe.
RlapsRisk BC uses AI to predict if a breast cancer patient will relapse after treatment and MSIntuit CRC pre-screens for the microsatellite instability biomarker in colon cancer tumors.
Digital pathology company Owkin is getting CE-mark for its diagnostics products in breast and colorectal cancer. The tests are being sold to pathology labs, oncologists, and surgeons.
Owkin has completed validation studies for each product, which will be published soon.
The breast cancer solution will also help care providers determine which patients may benefit from targeted medicine and which could avoid chemotherapy....